Project

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination with Acalabrutinib in Subjects with Relapsed/Refractory Dif-fuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia

Ongoing - recruitment active · 2021 until 2030

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment active
Start Date
2021
End Date
2030
Financing
Industry
Study Design
Phase 1b/2 Study
Keywords
CLL , DLBCL , Acalabrutinib , KRT 232 , Apoptose
Labels
lymphoma, leukemia
Brief description/objective

Aclabrutinib wird in Kombination mit KRT 232 bei R/R CLL und de novo R/R DLBCL jeweils TP 53 WT und BTK naiv eingesetzt. Initial Dosisescalations-stufe (Ib), anschlies-send Phase-II mit RP2D. Primärer Endpunkt: Dosisfin-dung/ Safety ; Efficacy in Phase II.